Latest news from Akari Therapeutics on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/expert-what-are-the-challenges-of-treating-orphan-diseases/?sc=rsin /articles/expert-what-are-the-challenges-of-treating-orphan-diseases/?sc=rsin Mon, 31 Oct 2016 08:50:30 EST Akari Therapeutics /articles/expert-scientists-turning-to-animal-kingdom-for-clues-to-new-drugs/?sc=rsin /articles/expert-scientists-turning-to-animal-kingdom-for-clues-to-new-drugs/?sc=rsin Mon, 08 Aug 2016 08:40:34 EST Expert can speak on the use of animal toxins to develop a new generation of medicines. Gur Roshwalb, MD, Chief Executive Officer of Akari Therapeutics, is studying the use of Coversin--a molecule derived from the saliva of the Ornithodoros moubata tick--in potential treatments for conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and Guillain Barre syndrome (GBS). Akari Therapeutics